Predicine will present three e-posters focusing on liquid biopsy methylation, urine biomarkers, and cfDNA+cfRNA molecular profiling, at the American Association for Cancer Research Virtual Meeting II, taking place June 22-24, 2020. For the first time, Predicine will present its proprietary methylation cell-free DNA (cfDNA) liquid biopsy technology for molecular methylation profiling in cancer patients, providing a non-invasive epigenetic approach to enabling early cancer detection, therapeutic monitoring, and minimal residual disease.
Presentation details are as follows:
Poster # 3670 | Session: Histone Modifications and Epigenomics
Development of cfDNA-based methylation assay for early cancer detection
Poster # 3098 | Session: Circulating Markers
Urine-based molecular biomarker signatures for bladder cancer
Poster # 3108 | Session: Circulating Markers
Combined cell-free DNA and cell-free RNA NGS testing for cancer patient care